Journal of Human Reproductive Sciences (Jan 2019)

A multicenter phase IV study to investigate the immunogenicity of recombinant human follicle-stimulating hormone and its impact on clinical outcomes in females undergoing controlled ovarian stimulation

  • Abha Majumdar,
  • Le Hoang,
  • Ly T Loc,
  • Padma Srivastava,
  • Chitra Ramamurthy,
  • Ratnabali Chakravorty,
  • Yogeshwar S Nandanwar,
  • M D Rashmi,
  • Rahul V Mayekar,
  • Jayashree Sridhar,
  • Ganesh H Divekar,
  • James John

DOI
https://doi.org/10.4103/jhrs.JHRS_33_19
Journal volume & issue
Vol. 12, no. 4
pp. 303 – 309

Abstract

Read online

Context: Therapeutic proteins can cause immune responses, which may have clinical implications. Aims: The aim of the study was to assess the immunogenicity of recombinant human follicle-stimulating hormone (r-hFSH), when used for controlled ovarian stimulation (COS). Settings and Design: Prospective, multicenter study conducted at reproductive medicine clinics in India and Vietnam. Materials and Methods: A total of 285 women, aged 20–40 years, undergoing 354 COS cycles for either intrauterine insemination (IUI) orin vitro fertilization (IVF) were studied. The primary outcome measure was the incidence of development of anti-drug antibodies (ADA) and their neutralization potential. Other outcome measures were follicle development, dose and duration of r-hFSH, positive serum pregnancy test, clinical pregnancy, cycle cancellation, and adverse events (AEs). Statistical Analysis Used: A sample size of 250 was planned. Descriptive statistics are presented. Results: Four patients tested positive for ADA after r-hFSH administration at different time points; all of them tested negative, subsequently. None were found to have neutralization potential. The mean dose and duration of r-hFSH were 816 IU and 8.1 days in IUI and 2183 IU and 9.5 days in IVF, respectively. The serum and clinical pregnancy rates were 12.4% and 11.6% in IUI and 32.7% and 29.9% in IVF cycles, respectively. Seven AEs were reported, including two cases of ovarian hyperstimulation syndrome; two AEs were judged to be serious. Conclusions: The tested r-hFSH has very low immunogenic potential and did not lead to the development of neutralizing antibodies. The overall efficacy and safety of the drug were in-line with existing literature data, and no specific clinical impact of immunogenicity could be identified.

Keywords